Back to Search
Start Over
Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib.
- Source :
-
Blood cancer journal [Blood Cancer J] 2018 Sep 03; Vol. 8 (9), pp. 88. Date of Electronic Publication: 2018 Sep 03. - Publication Year :
- 2018
- Subjects :
- Antineoplastic Agents administration & dosage
Antineoplastic Agents adverse effects
Dasatinib administration & dosage
Dasatinib adverse effects
Humans
Imatinib Mesylate pharmacology
Imatinib Mesylate therapeutic use
Leukemia, Myeloid, Accelerated Phase mortality
Neoplasm Staging
Protein Kinase Inhibitors administration & dosage
Protein Kinase Inhibitors adverse effects
Randomized Controlled Trials as Topic
Retreatment
Treatment Outcome
Antineoplastic Agents therapeutic use
Dasatinib therapeutic use
Drug Resistance, Neoplasm
Leukemia, Myeloid, Accelerated Phase drug therapy
Leukemia, Myeloid, Accelerated Phase pathology
Protein Kinase Inhibitors therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 2044-5385
- Volume :
- 8
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Blood cancer journal
- Publication Type :
- Editorial & Opinion
- Accession number :
- 30190469
- Full Text :
- https://doi.org/10.1038/s41408-018-0122-3